-
Hepatology | Long-term Prognosis and HCC Risk Stratification in Compensated Advanced Chronic Liver Disease Post-HCV Clearance
Chronic hepatitis C virus (HCV) infection is a major cause of cirrhosis and hepatocellular carcinoma (HCC). In recent years, the treatment of HCV infection has undergone revolutionary changes, transforming chronic HCV infection into a curable disease. Although direct-acting antiviral (DAA) therapy can effectively clear HCV, improve liver fibrosis, and reduce the risk of HCC, certain…
-
BOC/BOA 2024 | Professor Tiejun Gong: Interpretation of Three Major Studies in Hematologic Oncology
From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. Based on the actual situation of cancer incidence in China, the conference specially invited authoritative experts in the field of oncology and carefully selected outstanding papers…
-
BOC/BOA 2024 | Professor Jun Ma: Showcasing Oncology Frontiers and Uniting the Anti-Cancer Front for an Innovative Future
From July 5th to 7th, 2024, the Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO® 2024 China (BOC/BOA) were grandly held in Guangzhou. In the wake of ASCO’s profound impact, BOC/BOA gathered cutting-edge advancements from home and abroad, showcasing China’s innovative capabilities. With a special focus on hematologic malignancies and…
-
ASCO Hot Review丨Dr. Shanshan Wang: Multiple Prostate Cancer Studies Announced, Further Improving Patient Survival and Quality of Life
Prostate cancer incidence rates in China are currently surging, with high mortality rates and a significant disease burden. Various studies have actively explored ways to improve patients’ quality of life, and evidence for the combination of PARP inhibitors with NHA and immunotherapy has brought new options and hope for prostate cancer treatment. This year’s ASCO…
-
EHA International Perspective | Dr. Consuelo Bertossi: Key Findings on TP53 Mutations in Chronic Lymphocytic Leukemia (CLL)
TP53 mutations not only profoundly affect the progression trajectory of chronic lymphocytic leukemia (CLL), but are also directly associated with poor prognosis, becoming an important factor that cannot be ignored when assessing disease severity and formulating personalized treatment strategies. At the highly anticipated 29th Annual Congress of the European Hematology Association (EHA 2024), Dr. Consuelo…
-
Dr. Li Bao: Comprehensive Analysis of Hemophagocytic Lymphohistiocytosis (HLH) from Diagnosis to Treatment
On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of “Precision, Integration, Innovation,” the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024…
-
Dr. Kai Hu: The Application of Immunotherapy in Lymphoma and Myeloma | The 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference
On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of “Precision, Integration, Innovation,” the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024…
-
Dr. Lin Fu: On the Controversies and Advances in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)
On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of “Precision, Integration, Innovation,” the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024…
Connecting Medical Expertise through Media